About Rapport Therapeutics, Inc. Common Stock
https://www.rapportrx.comRapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
CEO
Abraham N. Ceesay
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 93
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
TRV GP V, LLC
Shares:7.14M
Value:$195.65M
FMR LLC
Shares:6.92M
Value:$189.66M
ARCH VENTURE MANAGEMENT, LLC
Shares:3.73M
Value:$102.24M
Summary
Showing Top 3 of 126
About Rapport Therapeutics, Inc. Common Stock
https://www.rapportrx.comRapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $29.99M ▲ | $-26.93M ▼ | 0% | $-0.71 ▲ | $-26.67M ▲ |
| Q2-2025 | $0 | $29.5M ▲ | $-26.73M ▼ | 0% | $-0.75 ▼ | $-29.24M ▼ |
| Q1-2025 | $0 | $27.11M ▲ | $-24.06M ▼ | 0% | $-0.12 ▼ | $-26.86M ▼ |
| Q4-2024 | $0 | $23.52M ▲ | $-19.98M ▼ | 0% | $-0.1 ▼ | $-23.26M ▼ |
| Q3-2024 | $0 | $21.64M | $-17.54M | 0% | $-0.09 | $-21.42M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $513.03M ▲ | $535.32M ▲ | $23.71M ▲ | $511.62M ▲ |
| Q2-2025 | $260.45M ▼ | $285.5M ▼ | $21.98M ▲ | $263.51M ▼ |
| Q1-2025 | $285.38M ▼ | $302.05M ▼ | $16.22M ▲ | $285.84M ▼ |
| Q4-2024 | $305.28M ▼ | $314.93M ▼ | $9.51M ▲ | $305.43M ▼ |
| Q3-2024 | $320.66M | $331.14M | $8.03M | $323.11M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-26.93M ▼ | $-17.46M ▲ | $-56.78M ▼ | $270.53M ▲ | $196.29M ▲ | $-17.6M ▲ |
| Q2-2025 | $-26.73M ▼ | $-25.07M ▼ | $22.6M ▲ | $-63K ▼ | $-2.54M ▼ | $-25.09M ▼ |
| Q1-2025 | $-24.06M ▼ | $-20.24M ▼ | $21.03M ▼ | $5K ▼ | $799K ▼ | $-20.53M ▼ |
| Q4-2024 | $-19.98M ▼ | $-14.45M ▲ | $31.93M ▲ | $7K ▲ | $17.49M ▲ | $-14.67M ▲ |
| Q3-2024 | $-17.54M | $-16.41M | $-53.04M | $-1.39M | $-70.85M | $-16.55M |
CEO
Abraham N. Ceesay
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 93
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
TRV GP V, LLC
Shares:7.14M
Value:$195.65M
FMR LLC
Shares:6.92M
Value:$189.66M
ARCH VENTURE MANAGEMENT, LLC
Shares:3.73M
Value:$102.24M
Summary
Showing Top 3 of 126